Professional Ad Reports
No one expected the numbers to be pretty. And medical/surgical journals' latest losses weren't. Larry Dobrow analyzes the numbers for the first half of 2013 by advertisers and brands
Pharma's turn to specialty drugs hasn't been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. Larry Dobrow reports the full-year numbers
Ad spend for medical/surgical journals declined by 16.5%, as patent expiries and regulatory delays stifled 2011's comeback bid. Marc Iskowitz reports on the numbers for the first half of 2012
Medical/surgical journal advertising grew in 2011, the second consecutive year it's been in the black. Marc Iskowitz on which categories and brands attracted the most advertising dollars
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.